| Shu, Yongqian |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
NCT06759636: FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 |
|
|
| Not yet recruiting | 3 | 88 | RoW | Romiplostim N01, Recombinant Human Interleukin-11 (rhIL-11) | The First Affiliated Hospital with Nanjing Medical University | CTIT: Cancer Therapy Induced Thrombocytopenia | 04/26 | 07/26 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
EXPLORING, NCT05494060: XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 80 | RoW | Anlotinib hydrochloride capsule, Penpulimab Injection, AK-105, XELOX, Capecitabine and Oxaliplatin | The First Affiliated Hospital with Nanjing Medical University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer, Digestive System Diseases, Gastric Cancer, Gastrointestinal Neoplasms | 12/24 | 02/27 | | |
TAXE-GC, NCT04963088: TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma |
|
|
| Recruiting | 1/2 | 66 | RoW | BGB-A317, Anlotinib, Oxaliplatin, Capecitabine | The First Affiliated Hospital with Nanjing Medical University | Gastric Cancer | 09/22 | 03/24 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
| chen, xiaofeng |
NCT06759636: FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 |
|
|
| Not yet recruiting | 3 | 88 | RoW | Romiplostim N01, Recombinant Human Interleukin-11 (rhIL-11) | The First Affiliated Hospital with Nanjing Medical University | CTIT: Cancer Therapy Induced Thrombocytopenia | 04/26 | 07/26 | | |
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
NCT06684158: Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC |
|
|
| Not yet recruiting | 2 | 70 | RoW | Mecapegfilgrastim, Adebrelimab, Docetaxel, Oxaliplatin, 5-Fluorouracil (5-FU), Leucovorin (LV) | The First Affiliated Hospital with Nanjing Medical University | GC/GEJC | 03/27 | 12/27 | | |
Modified, NCT06037655: Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC |
|
|
| Not yet recruiting | 2 | 30 | NA | Total Neoadjuvant Treatment | The First Affiliated Hospital with Nanjing Medical University | Biliary Tract Neoplasms | 03/26 | 12/26 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
